Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498

In DRAFT guidance, NICE recommends pembrolizumab as an option for untreated metastatic colorectal cancer in this setting provided it is stopped after 2 years and no documented disease progression, and it is supplied according to the commercial arrangement.

National Institute for Health and Care Excellence